`
`Euro
`
`500000 - Gross Sales 3P
`500100 - Sales Returns 3P
`501000 - Trade discounts (incl rebates)
`501100 - Cash discounts
`501900 - Other sales deductions
` ** I1010 - Net Sales
`
`FX
`
`USD
`
`500000 - Gross Sales 3P
`500100 - Sales Returns 3P
`501000 - Trade discounts (incl rebates)
`501100 - Cash discounts
`501900 - Other sales deductions
` ** I1010 - Net Sales
`
`USD
`USD
`USD
`USD
`USD
`USD
`
`Currency
`Euro
`Euro
`Euro
`Euro
`Euro
`Euro
`
`2009
`Sum of Q1
`
`2009
`Sum of Q2
`
`20,881
`
`(216)
`
`(2,124)
`
`(418)
`(54)
`
`
`18,070
`
`2009
`Sum of Q3
`
`7,555
`
`(902)
`
`(801)
`
`(151)
`
`(19)
`
`5,682
`
`2009
`Sum of Q4
`
`12,752
`
`(5,073)
`
`(1,287)
`
`(255)
`
`(32)
`
`6,106
`
`2009
`Sum of FY
`
`41,188
`
`(6,190)
`
`(4,213)
`
`(824)
`
`(105)
`
`29,857
`
`2010
`Sum of Q1
`
`17,191
`
`1,856
`
`(2,065)
`
`(344)
`
`(215)
`
`16,423
`
`2010
`Sum of Q2
`
`26,863
`
`621
`
`(3,049)
`
`(537)
`
`(336)
`
`23,562
`
`2010
`Sum of Q3
`
`31,313
`
`(775)
`
`(4,006)
`
`(626)
`
`(368)
`
`25,537
`
`2010
`Sum of Q4
`
`36,769
`
`(767)
`
`(5,108)
`
`(735)
`
`(448)
`
`29,711
`
`2010
`Sum of FY
`
`112,136
`
`934
`
`(14,228)
`
`(2,243)
`
`(1,367)
`
`95,233
`
`2011
`Sum of Q1
`
`40,188
`
`(804)
`
`(5,499)
`
`(804)
`
`(451)
`
`32,631
`
`2011
`Sum of Q2
`
`43,147
`
`(862)
`
`(4,993)
`
`(862)
`
`(386)
`
`36,044
`
`2011
`Sum of Q3
`
`49,184
`
`(982)
`
`(5,893)
`
`(982)
`
`(442)
`
`40,884
`
`2011
`Sum of Q4
`
`58,210
`
`(1,163)
`
`(8,145)
`
`(1,163)
`
`(524)
`
`47,216
`
`2011
`Sum of FY
`
`190,729
`
`(3,811)
`
`(24,530)
`
`(3,811)
`
`(1,803)
`
`156,774
`
`2012
`Sum of Q1
`
`69,880
`
`(1,398)
`
`(10,671)
`
`(1,398)
`
`(629)
`
`55,784
`
`2012
`Sum of Q2
`
`65,950
`
`(1,319)
`
`(10,093)
`
`(1,319)
`
`(594)
`
`52,626
`
`2012
`Sum of Q3
`81,218
`
`
`(772)
`
`(14,181)
`
`(1,624)
`
`168
`
`64,809
`
`2012
`Sum of Q4
`90,943
`
`
`(1,363)
`
`(14,682)
`
`(1,700)
`
`(638)
`
`72,560
`
`2012
`Sum of FY
`307,991
`
`
`(4,852)
`
`(49,627)
`
`(6,041)
`
`(1,692)
`
`245,779
`
`
`
`1.39
`
`
`
`1.39
`
`
`
`1.39
`
`
`
`1.39
`
`
`
`1.39
`
`
`
`1.32
`
`
`
`1.32
`
`
`
`1.32
`
`
`
`1.32
`
`
`
`1.32
`
`1.39
`
`1.39
`
`1.39
`
`1.39
`
`1.39
`
`
`
`1.29
`
`
`
`1.29
`
`
`
`1.29
`
`
`
`1.29
`
`
`
`1.29
`
`2009
`Sum of Q1
`-
`
`
`-
`
`-
`
`-
`
`-
`
`-$
`
`2009
`Sum of Q2
`
`29,046.55
`
`(299.97)
`
`(2,954.97)
`
`(580.93)
`
`(74.99)
`
`25,136$
`
`2009
`Sum of Q3
`
`10,509.39
`
`(1,254.19)
`
`(1,114.81)
`
`(210.20)
`
`(26.22)
`
`7,904$
`
`2009
`Sum of Q4
`
`17,738.44
`
`(7,056.18)
`
`(1,790.17)
`
`(354.74)
`
`(44.30)
`
`8,493$
`
`2009
`Sum of FY
`
`57,294.38
`
`(8,610.34)
`
`(5,859.95)
`
`(1,145.87)
`
`(145.51)
`
`41,533$
`
`2010
`Sum of Q1
`
`22,756.90
`
`2,456.31
`
`(2,733.45)
`
`(455.21)
`
`(284.47)
`
`21,740$
`
`2010
`Sum of Q2
`
`35,559.74
`
`822.25
`
`(4,035.76)
`
`(711.24)
`
`(444.50)
`
`31,190$
`
`2010
`Sum of Q3
`
`41,450.70
`
`(1,025.98)
`
`(5,303.56)
`
`(829.08)
`
`(487.68)
`
`33,804$
`
`2010
`Sum of Q4
`
`48,672.63
`
`(1,015.83)
`
`(6,761.23)
`
`(973.45)
`
`(592.78)
`
`39,329$
`
`2010
`Sum of FY
`
`148,439.97
`
`1,236.75
`
`(18,834.00)
`
`(2,968.97)
`
`(1,809.43)
`
`126,064$
`
`2011
`Sum of Q1
`
`55,860.91
`
`(1,117.12)
`
`(7,643.03)
`
`(1,117.12)
`
`(626.69)
`
`45,357$
`
`2011
`Sum of Q2
`
`59,973.96
`
`(1,198.18)
`
`(6,940.40)
`
`(1,198.18)
`
`(536.18)
`
`50,101$
`
`2011
`Sum of Q3
`
`68,365.91
`
`(1,365.54)
`
`(8,191.74)
`
`(1,365.54)
`
`(614.23)
`
`56,829$
`
`2011
`Sum of Q4
`
`80,912.06
`
`(1,616.38)
`
`(11,320.95)
`
`(1,616.38)
`
`(728.69)
`
`65,630$
`
`2011
`Sum of FY
`
`265,112.84
`
`(5,297.22)
`
`(34,096.12)
`
`(5,297.22)
`
`(2,505.80)
`
`217,916$
`
`2012
`Sum of Q1
`
`89,817.09
`
`(1,796.35)
`
`(13,715.66)
`
`(1,796.35)
`
`(808.36)
`
`71,700$
`
`2012
`Sum of Q2
`
`84,766.53
`
`(1,695.43)
`
`(12,972.46)
`
`(1,695.43)
`
`(762.94)
`
`67,640$
`
`2012
`Sum of Q3
`104,389.97
`
`
`(992.31)
`
`(18,226.46)
`
`(2,087.80)
`
`216.40
`
`83,300$
`
`2012
`Sum of Q4
`
`116,890.46
`(1,752.42)
`
`
`(18,871.00)
`(2,184.75)
`
`
`(820.10)
`
`93,262$
`
`2012
`Sum of FY
`
`395,864.05
`
`(6,236.51)
`
`(63,785.58)
`
`(7,764.33)
`
`(2,175.00)
`315,903$
`
`
`Argentum Pharm. v. Research Corp. Techs., IPR2016-00204
`RCT EX. 2175 - 1/2
`
`
`
`2013
`Sum of Q1
`82,887
`
`
`(1,243)
`
`(14,625)
`
`(1,658)
`
`(660)
`
`64,700
`
`2013
`Sum of Q2
`91,440
`
`
`(1,372)
`
`(16,185)
`
`(1,829)
`
`(732)
`
`71,323
`
`2013
`Sum of Q3
`109,324
`
`
`(1,715)
`
`(22,105)
`
`(2,186)
`
`(608)
`
`82,710
`
`2013
`Sum of Q4
`121,237
`
`
`(1,757)
`
`(28,312)
`
`(2,410)
`
`(1,034)
`
`87,725
`
`2013
`Sum of FY
`404,888
`
`
`(6,086)
`
`(81,227)
`
`(8,082)
`
`(3,034)
`
`306,459
`
`2014
`Sum of Q1
`112,428
`
`
`(1,125)
`
`(32,266)
`
`(2,249)
`
`(1,180)
`
`75,608
`
`2014
`Sum of Q2
`126,348
`
`
`(1,672)
`
`(43,083)
`
`(2,527)
`
`(700)
`
`78,367
`
`2014
`Sum of Q3
`142,674
`
`
`(2,061)
`
`(53,444)
`
`(2,854)
`
`(1,491)
`
`82,825
`
`2014
`Sum of Q4
`
`161,559
`
`11,904
`
`(74,387)
`
`(3,211)
`
`1,801
`
`97,666
`
`2014
`Sum of FY
`
`543,010
`
`7,046
`
`(203,180)
`
`(10,840)
`
`(1,570)
`
`334,466
`
`2015
`Sum of Q1
`
`162,654
`
`(2,440)
`
`(45,741)
`
`(3,253)
`
`(2,519)
`
`108,702
`
`2015
`Sum of Q2
`
`198,653
`
`(2,980)
`
`(53,776)
`
`(3,973)
`
`(2,586)
`
`135,339
`
`2015
`Sum of Q3
`
`204,621
`
`(3,070)
`
`(68,641)
`
`(4,093)
`
`94
`
`128,911
`
`2015
`Sum of Q4
`
`217,398
`
`(8,744)
`
`(65,695)
`
`(4,390)
`
`994
`
`139,563
`
`2015
`Sum of FY
`
`783,327
`
`(17,234)
`
`(233,853)
`
`(15,710)
`
`(4,016)
`
`512,515
`
`2016
`Q1
`
`236,465
`
`(3,547)
`
`(80,971)
`
`(4,729)
`
`(2,483)
`
`144,735
`
`2016
`Q2
`245,381
`
`
`(3,681)
`
`(91,011)
`
`(4,908)
`
`(2,713)
`
`143,068
`
`1.328
`
`1.328
`
`1.328
`
`1.328
`
`1.328
`
`1.325982377
`
`1.325982377
`
`1.325982377
`
`1.325982377
`
`1.325982377
`
`1.1089
`
`1.1089
`
`1.1089
`
`1.1089
`
`1.1089
`
`
`
`1.1028
`
`
`
`1.1288
`
`2013
`Sum of Q1
`110,073.87
`
`
`(1,651.11)
`
`(19,422.60)
`
`(2,201.48)
`
`(877.04)
`
`85,922$
`
`2013
`Sum of Q2
`121,432.02
`
`
`(1,821.48)
`
`(21,493.16)
`
`(2,428.64)
`
`(971.44)
`
`94,717$
`
`2013
`Sum of Q3
`145,181.86
`
`
`(2,277.43)
`
`(29,355.23)
`
`(2,902.39)
`
`(807.56)
`
`109,839$
`
`2013
`Sum of Q4
`161,003.16
`
`
`(2,332.65)
`
`(37,598.15)
`
`(3,199.87)
`
`(1,373.31)
`
`116,499$
`
`2013
`Sum of FY
`537,690.90
`
`
`(8,082.68)
`
`(107,869.14)
`(10,732.37)
`
`
`(4,029.35)
`
`406,977$
`
`2014
`Sum of Q1
`149,076.96
`
`
`(1,492.35)
`
`(42,784.21)
`
`(2,981.54)
`
`(1,564.61)
`
`100,254$
`
`2014
`Sum of Q2
`167,535.79
`
`
`(2,216.99)
`
`(57,126.94)
`
`(3,350.72)
`
`(928.15)
`
`103,913$
`
`2014
`Sum of Q3
`189,183.86
`
`
`(2,732.79)
`
`(70,865.95)
`
`(3,783.97)
`
`(1,976.46)
`
`109,825$
`
`2014
`Sum of Q4
`
`214,224.96
`
`15,784.69
`
`(98,635.99)
`
`(4,257.78)
`
`2,387.83
`
`129,504$
`
`2014
`Sum of FY
`
`720,021.56
`
`9,342.55
`
`(269,413.09)
`
`(14,374.01)
`
`(2,081.38)
`
`443,496$
`
`2015
`Sum of Q1
`
`180,366.98
`
`(2,705.23)
`
`(50,722.29)
`
`(3,607.34)
`
`(2,792.98)
`
`120,539$
`
`2015
`Sum of Q2
`
`220,286.75
`
`(3,304.30)
`
`(59,631.82)
`
`(4,405.74)
`
`(2,867.37)
`
`150,078$
`
`2015
`Sum of Q3
`
`226,904.42
`
`(3,404.28)
`
`(76,116.05)
`
`(4,539.04)
`
`104.78
`
`142,950$
`
`2015
`Sum of Q4
`
`241,072.80
`
`(9,696.56)
`
`(72,849.22)
`
`(4,868.17)
`
`1,102.75
`
`154,762$
`
`2015
`Sum of FY
`
`868,630.95
`
`(19,110.38)
`
`(259,319.37)
`
`(17,420.29)
`
`(4,452.82)
`
`568,328$
`
`2016
`Q1
`260,785.87
`
`
`(3,911.79)
`
`(89,299.05)
`
`(5,215.72)
`
`(2,738.25)
`
`159,621$
`
`2016
`Q2
`
`276,996.01
`
`(4,154.97)
`
`(102,737.03)
`
`(5,539.96)
`
`(3,062.53)
`
`161,502$
`
`Argentum Pharm. v. Research Corp. Techs., IPR2016-00204
`RCT EX. 2175 - 2/2